Last reviewed · How we verify
Atezolizumab Injection
Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.
Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity. Used for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Hepatocellular carcinoma.
At a glance
| Generic name | Atezolizumab Injection |
|---|---|
| Also known as | Atezolizumab, Tecentriq |
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Atezolizumab binds to programmed death ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors on T cells. This blockade restores exhausted T-cell function, allowing enhanced recognition and killing of cancer cells. By targeting PD-L1 rather than PD-1, it may also deplete PD-L1-expressing regulatory T cells and myeloid-derived suppressor cells.
Approved indications
- Metastatic non-small cell lung cancer (NSCLC)
- Metastatic urothelial carcinoma
- Hepatocellular carcinoma
- Gastric or gastroesophageal junction adenocarcinoma
- Colorectal cancer (in combination with chemotherapy)
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Diarrhea
- Cough
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (PHASE1)
- Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (PHASE2, PHASE3)
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atezolizumab Injection CI brief — competitive landscape report
- Atezolizumab Injection updates RSS · CI watch RSS
- Federation Francophone de Cancerologie Digestive portfolio CI